Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points

被引：7
|
作者：
Law, Ernest [1 ]
Gavanji, Roya [2 ]
Walsh, Sarah [3 ]
Haltner, Anja [3 ]
McTavish, Rebecca [2 ]
Cameron, Chris [3 ]
机构：
[1] Pfizer, New York, NY 10017 USA
[2] EVERSANA, Burlington, ON L7N 3H8, Canada
[3] EVERSANA, Sydney, NS B1P 1C6, Canada
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 11卷 / 02期
关键词：
abemaciclib; advanced breast cancer; health-related quality of life; HER2-negative; hormone receptor-positive; indirect treatment comparison; matching-adjusted indirect comparison; palbociclib; patient-reported outcomes; quality of life; QUALITY-OF-LIFE; MONARCH; 2; ABEMACICLIB; PLUS FULVESTRANT; COMBINATION; GUIDELINES; OUTCOMES; WOMEN; CARE;
D O I：
10.2217/cer-2021-0221
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: To assess the relative impact of palbociclib plus fulvestrant (PAL + FUL) and abemaciclib plus fulvestrant (ABEM + FUL) on patient-reported outcomes in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer. Patients & methods: Anchored matching-adjusted indirect comparisons were conducted using individual patient data from PALOMA-3 (PAL + FUL) and summary-level data from MONARCH-2 (ABEM + FUL). Outcomes included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) and its breast cancer-specific module (QLQ-BR23). Results: Significantly different changes from baseline favoring PAL + FUL compared with ABEM + FUL were observed in global quality of life (6.95 [95% CI: 2.19-11.71]; p = 0.004) and several functional/symptom scales, including emotional functioning, nausea/vomiting, appetite loss, diarrhea and systemic therapy side effects. Conclusion: PAL + FUL was associated with more favorable patient-reported outcomes than ABEM + FUL in patients with HR+/HER2- advanced breast cancer.
引用
收藏
页码：109 / 120
页数：12
相关论文
共 50 条
  • [1] Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-advanced breast cancer
    Tremblay, Gabriel
    Chandiwana, David
    Dolph, Mike
    Hearnden, Jaclyn
    Forsythe, Anna
    Monaco, Mauricio
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1319 - 1327
  • [2] Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Barriga, Susana
    Lin, Yong
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [4] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
    Mitra, D.
    Darden, C.
    McSorley, D.
    Davis, K.
    Band, J.
    Iyer, S.
    VALUE IN HEALTH, 2018, 21 : S36 - S36
  • [5] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [6] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [7] Patient-reported pain severity, pain interference and health status in HR+/HER2-advanced/metastatic breast cancer
    Wood, Robert
    Mitra, Debanjali
    de Courcy, Jonathan
    Iyer, Shrividya
    ESMO OPEN, 2017, 2 (03)
  • [8] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2-advanced breast cancer: a matching-adjusted indirect comparison
    Rugo, Hope S. S.
    Harmer, Victoria
    O'Shaughnessy, Joyce
    Jhaveri, Komal
    Tolaney, Sara M. M.
    Cardoso, Fatima
    Bardia, Aditya
    Maheshwari, Vikalp Kumar
    Tripathi, Sandeep
    Haftchenary, Sina
    Pathak, Purnima
    Fasching, Peter A. A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [10] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
12345